ToleroMune Ragweed Follow up Study

Status Completed

Clinical Trial Summary

Ragweed is the primary cause of autumn allergies. The ragweed season begins in mid-August. In the third National Health and Nutrition Examination Surveys54.3% of the population had positive test responses to one or more allergens, with the prevalence for short ragweed being 26.2%

The purpose of this observational follow-on study is to further evaluate rhinoconjunctivitis symptoms on exposure to ragweed allergen in the EEC among subjects who completed all dosing visits and the post treatment challenge (PTC) visit in study TR002 approximately one year after the start of treatment.

Clinical Trial Description

Subjects who were randomised in study TR002 and who completed all dosing visits and the PTC will be invited to attend the Screening Visit for TR002B. Subjects will attend the EEC for 4 visits on successive days. Following the final EEC visit a follow-up visit will be performed 3-10 days later. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01448603
Study type	Observational
Source	Circassia Limited
Contact
Status	Completed
Phase	N/A
Start date	October 2011
Completion date	March 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05560698` - A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment	N/A
Completed	`NCT02849210` - A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea	Phase 1
Completed	`NCT02340130` - Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma	Phase 2
Completed	`NCT02150343` - Phase II HDM-SPIRE Safety and Efficacy Study	Phase 2
Completed	`NCT01949428` - House Dust Mite Observational Study	N/A
Completed	`NCT01949415` - An Optional Investigation of Biomarkers of Efficacy	N/A
Completed	`NCT01949441` - ToleroMune House Dust Mite (HDM) Tolerability Study	Phase 2
Completed	`NCT01923792` - ToleroMune House Dust Mite Follow on Study	N/A
Completed	`NCT01447784` - ToleroMune House Dust Mites (HDM) Exposure Chamber Study	Phase 2
Recruiting	`NCT04435990` - Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites	Phase 3
Recruiting	`NCT05960266` - Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study	Early Phase 1
Completed	`NCT01720251` - Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy	Phase 2
Completed	`NCT01620762` - Phase III Cat-PAD Study	Phase 3
Completed	`NCT01353755` - 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma	Phase 3
Completed	`NCT00574210` - PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)	Phase 2
Completed	`NCT00537342` - Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT)	Phase 3
Completed	`NCT00540631` - Multicenter Trial of Immunotherapy With House Dust Mite Allergoid	Phase 3
Completed	`NCT05540717` - Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen	Phase 3
Completed	`NCT02844842` - Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
Completed	`NCT01734265` - Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).	Phase 2